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Sodium butyrate (NaBu) has been used as a productivity enhancer for the synthesis of recombinant proteins in Chinese hamster
ovary (CHO) cells. Thus, the inﬂuence of NaBu on the production of recombinant human prolactin (hPRL) from CHO cells was
investigated for the ﬁrst time. CHO cell cultures were submitted to a treatment with diﬀerent concentrations of NaBu (0.25 to
4mM). Quantitative and qualitative analyses by reverse-phase high-performance liquid chromatography (RP-HPLC) and Western
blot or SDS-PAGE, carried out directly on CHO-conditioned medium, showed that the highest hPRL expression was obtained
with 1mM NaBu. In vitro biological assays based on noble rat lymphoma (Nb2) and mouse pro-B lymphoma (Ba/F3-LLP) cells
were carried out on puriﬁed hPRL. Its bioactivity in the presence of NaBu was not apparently diﬀerent from that of the First
International Reference Reagent of recombinant hPRL (WHO 97/714). Our results show that NaBu increased the synthesis of
recombinant hPRL in CHO cells, apparently without compromising either its structure or function.
1.Introduction
Human prolactin (hPRL), a 23kDa polypeptide hormone
with a single chain of 199 residues, is a member of the family
of cytokines, which includes erythropoietin, interleukin-
6, and many others, but is most closely related, both
evolutionarily and functionally, to human growth hormone
and placental lactogen [1]. This polypeptide is known to be
involved in a variety of actions [2], more than all the other
pituitary hormones combined, such as cell proliferation,
growth and development, water and electrolyte balance, and
several physiological and behavioral aspects of mammal,
bird, and reptile reproduction [3]. In humans, prolactin
is secreted by pituitary lactotrophs under hypothalamic
regulation. It circulates in the bloodstream and acts distally
as an endocrine hormone. Apart from the pituitary, many
extrapituitary sites for hPRL synthesis have been docu-
mented, including breast, prostate, and female reproductive
tract, where it appears to act locally to regulate cellular
growth and diﬀerentiation [1, 4, 5] .T h eh P R Lg e n eh a sb e e n
cloned and the authentic form of the hormone eﬃciently
expressed in bacterial periplasm and in Chinese hamster
ovary (CHO) cells in our laboratory [6–8]. Since hPRL is
one of the hormones most frequently determined in routine
clinical assays and several therapeutic applications are being
considered, an increasing need for pure bioactive hPRL can
be anticipated [9, 10].
Sodium butyrate (NaBu) is a short chain fatty acid,
originally identiﬁed as a product of anaerobic bacterial
fermentation, which has been shown to alter the structure
of chromatin in the nucleus of mammalian cells by reducing
the activity of histone deacetylase [11]. One of the possible
causes for improved gene expression by NaBu cells is histone
hyperacetylation, which facilitates the access of general tran-
scription factors in eukaryotic cells [12, 13]. However, NaBu
can also cause a cellular arrest, leading to increased apoptosis
and resulting in an overall reduction in recombinant protein
production over longer periods of time [14].2 Journal of Biomedicine and Biotechnology
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Figure 1: NaBu inﬂuence on cellular growth and viability of hPRL-secreting CHO cells. (a) Cellular growth and (b) cellular viability in a 10-
day hPRL production period under diﬀerent NaBu concentrations. Thecell viability was determined by thetrypan blue exclusion procedure,
following trypsinization. Values are the mean of two independent determinations.
NaBu treatment has been shown, via immunoassay
determination, to increase the expression levels of foreign
proteins such as human thrombopoietin, interferon-β-1a,
and chimeric IgG3 antibodies in CHO cell cultures [15–17]
by factors of 2-, 2.5-, and 3.6-fold, respectively, relative to
nontreated cells. This led us to investigate, for the ﬁrst time,
via physicochemical techniques, whether addition of NaBu
wouldalsoincreasehPRLproductioninthesecellcultures.In
order to characterize the product obtained, we took advan-
tage of a speciﬁc RP-HPLC methodology previously devel-
oped in our laboratory [18], which permits qualitative and
quantitative analysis of hPRL directly in CHO-conditioned
medium. High-Performance Size-Exclusion Chromatogra-
phy (HPSEC) methodology was used for both analytical and
preparative purposes [19] and also allowed us to evaluated
hPRL activity directly in two bioassays, after its puriﬁcation
from CHO-conditioned medium [9].
2.MaterialsandMethods
2.1. Cell Culture. The clone expressing hPRL, derived from
CHO dhfr− cells (DUKX-B11) that had been transfected
withthevectorpEDdc-hPRL,wasobtainedinourlaboratory
[8]. Cells were thawed into T-ﬂasks (75cm2, from Corning
CostarCorporation,Cambridge,MA)containingα-minimal
essential medium (α-MEM, Gibco-Invitrogen Corporation,
Grand Island, NY, USA) with L-glutamine and without
ribonucleosides and deoxyribonucleosides, supplemented
with 10% dialysed fetal bovine serum (dFBS), 40μg/mL gen-
tamycin, 4g/L glucose, and 100nM methotrexate. Cultures
were maintained in a humidiﬁed incubator at 37◦C in the
presence of 5% CO2.
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Figure 2: Electrophoretic patterns of DNA isolated from NaBu-
treated and untreated CHO cells. Isolated chromosomal DNA
(2μg) was electrophoresed on 5% polyacrylamide gel and intact
and fragmented DNA bands were revealed by silver staining.
Arrowheads designate DNA ladder formation. M: molecular weight
marker, 100-bp DNA ladder. DNAs were isolated from day 8
cultures exposed to diﬀerent concentrations of Nabu.
2.2. NaBu Treatment. 100mM NaBu was prepared in
phosphate-buﬀered saline (PBS) (0.007M Na2HPO4,0 . 0 1M
NaH2PO4, pH 7.4 and 0.15M NaCl), sterilized by passingJournal of Biomedicine and Biotechnology 3
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Figure 3:OverlayofRP-HPLCqualitativeandquantitativeanalyses
ofhPRLsecretedbyCHOcellstreatedwithdiﬀerentconcentrations
of NaBu. IR: Internal Reference Preparation of periplasmic E. coli-
derived hPRL (7.0μg). mAbs: milliabsorbance.
through a 0.20μm syringe ﬁlter (Corning Incorporated,
Corning, NY, USA), and stored in aliquots at −20◦C. To
examine the eﬀect of diﬀerent concentrations of NaBu
on hPRL production, 1mL of CHO cell suspension (5 ×
104 cells/mL) was seeded into each well of a 24-well plate
to obtain a concentration of 2 × 105 cells/mL. Cultures were
then rinsed twice in PBS to remove serum and medium.
Fresh medium was then added containing NaBu to a ﬁnal
concentration between 0 and 4mM. Cells were grown for 10
days and CHO cell-conditioned medium was collected daily
a n ds t o r e da t−80◦C for subsequent RP-HPLC or Western
blot analysis.
For product puriﬁcation, CHO cells were expanded
into ten T-ﬂasks, in α-MEM supplemented with dFBS,
until they were conﬂuent. Cultures also were rinsed twice
in PBS to remove serum and medium. When the cell
density was ∼ 2 × 105 cells/mL, fresh medium was then
added to the T-ﬂasks: ﬁve contained no NaBu, while the
chosen amounts of NaBu were added to the other ﬁve.
ThehPRL-secretingconﬂuentcultureswerethenmaintained
for up to ten days by replacing the medium every 24
hours. The conditioned medium was collected and stored,
as mentioned above, for SP-Sepharose Fast Flow and HPSEC
puriﬁcation.
2.3. Cell Counts. To examine the eﬀect of diﬀerent con-
centrations of NaBu on cell density and viability, 1mL of
CHO cell suspension (5 × 104 cells/mL) was seeded into
each well of a 24-well plate to obtain a concentration of
2 × 105 cells/mL. NaBu was added to a ﬁnal concentration
between 0 and 4mM and cells were grown for 10 days,
as mentioned above. Every 24 hours a sample for the
diﬀerent concentrations of NaBu was detached from 24-
well plate by treatment with 0.025% trypsin-EDTA in PBS.
Total cell number and viability were determined by using
the Trypan blue (Gibco-Invitrogen Corporation) exclusion
methodviahaemocytometryandphasecontrastmicroscopy,
to distinguish viable and nonviable cells on the basis of dye
uptake [20].
2.4. DNA Fragmentation Assay by Electrophoresis. 5 ×
104 cells/mL cells were seeded in 24-well plate, treated
and detached at regular times, as mentioned above. 1 ×
106 cells/mL per sample were lysed in 400μLo fl y s i sb u ﬀer
(50mM Tris, 10mM EDTA pH 8.0, 1% SDS) and 500μg/mL
proteinase K (Fermentas, Life Sciences, S˜ ao Paulo, Brazil)
at 37◦C for 16 hours. The lysates were extracted with
phenol:clorophorm:isoamylalcohol (25:24:1). DNA was
precipitated with 100% ice-cold ethanol. The resulting pel-
lets ofDNA wereresuspendedin TEbuﬀer(pH 8.0) [14]and
treated with 10μg/mL RNase A (Fermentas, Life Sciences,
Brazil)priortoelectrophoresisona5%polyacrylamidegelat
70V [21]. Intact and fragmented DNA bands were revealed
by silver staining.
2.5. Gel Electrophoresis and Western Blot Analysis. Discon-
tinuous SDS-PAGE, based on 15% polyacrylamide gels, was
carried out under nonreducing conditions as described by
Laemmli [22]. Proteins were revealed by silver or Coomassie
brilliant blue G-250 (USB, Cleveland, OH) staining. The
molecularmassmarkerswerepurchasedfromGEHealthcare
Bio-Science Corp. (Piscataway, NJ, USA). Western blot
analysis was performed according to Bannerman et al. [23],
using 125I-labelled protein A [24] and anti-hPRL antiserum
obtainedinrabbitandvalidatedinourlaboratoryagainstthe
NIDDK-anti-hPRL-3 from National Hormone and Pituitary
Program, Torrance, CA, USA [7, 8].
2.6. Protein Determination. Total protein content was deter-
minate by BCA protein assay, using bicinchoninic acid
(Micro BCA protein assay kit, Pierce, Rockford, IL, USA).
Pure bovine serum albumin (BSA, Sigma, S˜ ao Paulo, Brazil)
was used as standard.
2.7. Reversed-Phase High-Performance Liquid Chromatogra-
phy (RP-HPLC). After the treatment with diﬀerent NaBu
concentrations, an aliquot of conditioned culture medium
(∼10mL) was concentrated (∼10fold) by using a centrifugal
membrane ﬁlter Ultra 4 (Amicon, Millipore Corporation,
Billerica, MA, USA) and applied to a RP-HPLC column. A
Shimadzu Model SCL-10A HPLC apparatus coupled to a
SPD-10AV UV detector (Shimadzu, MD, USA) was used,
employing the Class VP software, also from Shimadzu.
The column was a C4 Vydac 214TP54 (25cm × 4.6mm
id, pore diameter of 300 ˚ A and particle diameter of 5μm)
with a silica precolumn packed with LiChrosorb Si-60, 7.9–
12.4μm (Merck, Darmstadt, Germany) located between the
pump and the injector. All Vydac columns were purchased
from Grace Vydac (Hesperia, CA, USA). The mobile phase
consisted of 71% Tris-HCl buﬀer (50mM, pH 7.5) and
29% n-propanol, as described by Dalmora et al. [19], with
a ﬂow-rate of 0.5mL/min, a detector wavelength of 220nm,
a column temperature maintained at 45◦C, and a sample
volume of 25–500μL[ 18]. This methodology was used for
analytical purposes to examine the eﬀect of NaBu on hPRL
production.4 Journal of Biomedicine and Biotechnology
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Figure 4: Western blot analysis of hPRL production in CHO cells treated with diﬀerent concentrations of NaBu on days 1 (a), 4 (b), 5 (c),
and 6 (d). Molecular weights G-hPRL (25kDa) and NG-hPRL (23kDa) are indicated. IR: Internal Reference of periplasmic E. coli-derived
hPRL.
2.8. High-Performance Size-Exclusion Chromatography
(HPSEC). The HPSEC is an entropically controlled sepa-
ration technique in which molecules are separated on the
basis of their hydrodynamic molecular volume or size
[25, 26]. This methodology was used for both analytical
and preparative purposes and allowed us to use puriﬁed
hPRL directly in bioassays, the n-propanol interference
being absent due to the RP-HPLC technique. HPSEC was
carried out with the same Shimadzu apparatus, processing
25 to 500μL of sample on a TosoHaas (Montgomeryville,
PA, USA) G2000 SW column (60cm × 7.5mm i.d., particle
size of 10μm and pore size of 125 ˚ A) coupled to a 7.5cm
× 7.5mm i.d. SW guard column. The mobile phase was
0.025M ammonium bicarbonate, pH 7.0, with a ﬂow-rate
of 1.0mL/min [19].
2.9. hPRL Puriﬁcation. The hPRL present in conditioned
culture medium was puriﬁed as described by Soares et al.
[9]. A two-step puriﬁcation process was used: SP-Sepharose
Fast Flow followed by a size exclusion chromatographyJournal of Biomedicine and Biotechnology 5
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Figure 5: (a) Western blot analysis and (b) SDS-PAGE stained with AgNO3 of 10-day production pools of hPRL secreted by CHO cells
treated with diﬀerent NaBu concentrations. IR: Internal Reference of periplasmic E. coli-derived hPRL. Mr: molecular mass marker.
employing HPSEC for preparative purposes. Brieﬂy, condi-
tioned medium (∼500mL) was adjusted to pH 5.0 using
acetic acid. The material was then applied onto the SP-
Sepharose Fast Flow column (GE Healthcare Bio-Science
Corp., Piscataway, NJ, USA) equilibrated in 50mM sodium
acetate, pH 5.0. UV absorbance was monitored at 280nm.
After washing with the same buﬀer, the column was treated
with 50mM sodium acetate, pH 5.0, 90mM NaCl buﬀer.
The protein of interest was then eluted from the column
with 25mM Hepes, pH 8.0. Diﬀerent fractions containing
hPRL were analysed by HPSEC and the most concentrated
fractionswerepuriﬁedonthesameHPSECcolumn,working
this time in a preparative mode. The maximum volume
applied in each preparative HPSEC run was 500μL. hPRL
in the ﬁnal pool obtained via the HPSEC puriﬁcation was
quantiﬁed for bioassay purposes by HPSEC and stored at
−80◦C.
2.10. In Vitro Bioassay. The biological activity of puriﬁed
hPRL was determined via the Nb2 and Ba/F3-LLP lym-
phomacell-proliferationassays,aspreviouslydescribed[27],
against the First WHO Reference Reagent of recombinant
hPRL, lyophilized in ampoules coded 97/714 [28].
Ba/F3-LLP cells were routinely maintained in suspension
in RPMI-1640 medium supplemented with 10% heat-
inactivated FBS, 2mM glutamine, 50U/mL of penicillin,
50μg/mL of streptomycin, 700μg/mL of geneticin and
1ng/mL of hPRL. Before carrying out the proliferation
assay, cells were starved for 6 hours in the RPMI-1640
medium, as mentioned above, without hPRL. Cells were
then distributed in ﬂat bottom 96-well plates at a density
of 5 × 104 cells/well in a ﬁnal volume of 200μL. After 72
hours at 37◦C and 5% CO2, the presence of viable cells was
assessed using MTS assay [29]. Brieﬂy, 2mg/mL MTS dye
[3(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-
2-(4-sulf-ophenyl)-2H-tetrazolin (Promega Corp., Madison,
WI,USA)] in PBS was mixed in a 20:1 ratio (vol/vol) with
Table 1: Expression levels and RP-HPLC retention times (tR)o f
hPRL obtained from CHO cells treated with diﬀerent concentra-
tions of NaBu for 10 days. The tR were compared with those of the
Internal Reference Preparation of periplasmic E. coli-derived hPRL
(tR :2 6 .00 ±0.72 minutes).
NaBu (mM) Expression levels of
hPRL
a (μg/mL) tR
a (min)
0 0.92 ± 0.22 25.81 ± 0.52
0.25 1.30 ± 0.06 25.68 ± 0.47
0.5 1.67 ± 0.00 25.90 ± 0.77
1 2.00 ± 0.03 25.77 ± 0.73
2 1.48 ± 0.05 25.66 ± 0.87
4 1.23 ± 0.11 25.68 ± 0.82
Average tR = 25.75 ± 0.09
RSD = 0.4%
aEach value is the mean ± SD of duplicate experiments.
PMS (phenazine methosulphate) (Sigma, St. Louis, MO,
USA), 0.92mg/mL in PBS. Twenty microliters of mixture
were then added to each well, and 2 hours after incubation
at 37◦C the absorbance at 490nm was read in a microplate
reader (Multiskan EX Thermo Electron Corporation,
Vantaa, Finland).
Nb2 cells also routinely maintained in suspension
in RPMI-1640 medium supplemented with 10% heat-
inactivatedFBS,2mMglutamine, 50U/mL ofpenicillin, and
50μg/mL of streptomycin mixed in a 50:1 ratio (vol/vol)
with 5mM 2-β mercaptoethanol in PBS. Before carrying out
the proliferation assay, cells were maintained in the RPMI-
1640, as mentioned above, containing 1% heat-inactivated
FBS for 8 hours, constituting the preassay. Afterward, the
cellsweredistributedinﬂatbottom96-wellplatesatadensity
of 2 × 104 cells/well in a ﬁnal volume of 200μL, with no
heat-inactivated FBS addition. After 72 hours at 37◦Ca n d6 Journal of Biomedicine and Biotechnology
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Figure 6: Example of chromatographic puriﬁcation of hPRL on SP-Sepharose Fast Flow and SDS-PAGE analysis of CHO cell-conditioned
medium of (a) nontreated cells and (b) cells treated with 1mM NaBu. Lane 1: molecular mass marker. Lane 2: Chemical Reference Standard
of G-hPRL and NG-hPRL (WHO-CRS). Lane 3: Internal Reference of periplasmic E. coli-derived hPRL. Lane 4: CHO-conditioned medium.
Lane 5: unretained fraction. Lanes 6–8: fractions eluted with 25mM HEPES, pH 8.0. NaAc: sodium acetate.
5% CO2, the presence of viable cells was assessed using MTS
assay, as mentioned before.
3. Results
3.1. Cell Growth and Viability. The inﬂuence of diﬀerent
concentrations of NaBu on hPRL-secreting CHO cellular
growth and viability during a 10-day culture can be seen
in Figure 1. The treatment with either 0.25 or 0.5mM
NaBu did not result in signiﬁcant growth inhibition (P>
0.05) compared to the control without NaBu (Figure 1(a)).
Nonetheless, a dose response-eﬀect on cellular growth was
observed in the concentration range of 1 to 4mM NaBu,
with a dramatic fall already occurring after day 2 at the
concentrations of 2mM and 4mM NaBu. The treatment
with 1mM NaBu produced an apparent decline only 4 days
afterstartingthetreatment.Withregardtocellviability,none
of the concentrations except 4mM NaBu (P<0.05) showed
any signiﬁcant eﬀect (Figure 1(b)).Journal of Biomedicine and Biotechnology 7
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Figure 7: (a) and (b) Qualitative and quantitative HPSEC analysis of NaBu-treated and untreated CHO-derived hPRL after SP-Sepharose
Fast Flow and (c) after preparative HPSEC puriﬁcation, comparing the product obtained from tube #28 of nontreated (a) and NaBu-treated
cells (b). IR: Internal Reference of periplasmic E. coli-derived hPRL (7.0μg). mAbs: milliabsorbance. Tube numbers (#27, #28, and #29) are
from SP-Sepharose chromatography. Retention Times (tR) are indicated.
The rate of apoptosis in NaBu-treated and untreated
CHOcellswasexaminedbypolyacrylamidegelelectrophore-
sis and revealed by silver staining. Figure 2 shows that NaBu-
treated and untreated CHO cells exhibit oligonucleosomal
DNA ladder which is the hallmark of apoptosis, resulting
from endonuclease activity at internucleosomal sites in an
apoptotic cell. The intensity of the oligonucleosomal DNA
ladder seems NaBu dose-dependent. On the other hand,
the progressive removal of dFBS from the culture medium
could also be associated with apoptotic cell death in NaBu-
treated and untreated CHO cells, leading to a decrease of
cellular growth after day 5. This can be due to the fact that
serum contains growth factors that help the culture survival
[30].
3.2. Eﬀe c to fN a B uo nh P R LP r o d u c t i o n . A RP-HPLC meth-
odology, previously set up in our laboratory speciﬁcally
for hPRL qualitative and quantitative analysis [18], was
then employed to quantify hPRL production and detect
the presence of possible alteration in hPRL structure or
hydrophobicity due to the prolonged presence of NaBu. The
data in Table 1 and Figure 3 show that 1mM NaBu is capable
of greatly increasing hPRL synthesis (P<0.02), with no
signiﬁcant diﬀerences (P>0.05) in the retention time (tR)
of the resultant hPRL up to 4mM NaBu.
HumanprolactinquantiﬁcationcarriedoutbyRP-HPLC
in CHO cell-conditioned medium (Table 1) indicated that
the highest production was obtained with 1mM NaBu,
which increased the secretion ∼2-fold relative to control
cultivation without NaBu addition. Despite an increase in
protein expression, the concentrations of 0.5mM and 2mM
NaBu provided lower hPRL volumetric yields than 1mM
NaBu. The greatest inhibition of cell growth was produced
by 4mM NaBu leading to lower hPRL synthesis (Figure 1(a)
and Table 1). Clearly, it will be important to determine the
optimal NaBu concentration in long-term cell cultures.
ToconﬁrmtheexpressionandpuritylevelofhPRL,equal
volumes of CHO-conditioned medium, collected on days
1, 4, 5, and 6, were analyzed by Western blot (Figure 4);
the same was done with pools obtained after 10 days of
cultivation (Figure 5(a)). These pools were also analyzed via
SDS-PAGE followed by AgNO3 staining (Figure 5(b)), which
demonstrated the predominance, with 1mM NaBu, of hPRL
relative to other proteins that might be present in CHO
cell-conditioned medium. Taken together, these RP-HPLC,
Western blot, and SDS-PAGE analyses indicate that, under
our conditions, 1mM NaBu was the ideal concentration,
providing the highest hPRL expression level, while still
maintaining good cell viability and only a limited decrease
in cell growth.8 Journal of Biomedicine and Biotechnology
Table 2: Recombinant hPRL puriﬁcation starting from 500mL of NaBu-treated or untreated CHO-conditioned medium.
Puriﬁcation step Total protein (mg)
a hPRL (mg) Mass fraction
0mM NaBu 1mM NaBu 0mM NaBu 1mM NaBu 0mM NaBu 1mM NaBu
Conditioned medium 64.7 66.2 0.54 1.20b 0.008 0.018
SP-Sepharose FF 2.3 3.0 0.51 1.22c 0.219 0.403
Preparative HPSEC 0.14 0.25 0.13 0.25c 0.978 1.000
aEstimated by BCA assay. bEstimated by RP-HPLC. cEstimated by HPSEC.
Table 3: Bioactivity of puriﬁed hPRL obtained from CHO cells
treated or not with NaBu, determined via Nb2 or Ba/F3-LLP cells
against the First International Standard for recombinant hPRL
(WHO 97/714) with an activity of 57.2 ± 11.4IU/mg.
IU/mg hPRLa
Cells 0mM NaBu 1mM NaBu
Nb2 50.88 ± 5.33 61.21 ± 4.66
Ba/F3-LLP 50.07 ± 5.64 71.47 ± 4.33
aValues are means ± SD of two independent assays, each run with intra-
assay quadruplicates.
SP-Sepharose Fast Flow chromatographic puriﬁcation of
NaBu-treated and untreated cells, together with SDS-PAGE
analysis of applied and eluted fractions, is shown in Figure 6.
This conﬁrmed the presence of about twice as much hPRL
in the medium treated with 1mM NaBu and the eﬃcient
adsorption of both the 25kDa glycosylated (G-hPRL) and
the 23kDa nonglycosylated hPRL (NG-hPRL) isoforms by
the cationic exchanger [31].
The same partially puriﬁed products were also analyzed
by HPSEC before and after using this same column for
preparative purposes (Figures 7(a), 7(b),a n d7(c)). The
purity obtained for both products after this second chro-
matographic step is noteworthy (>97%) (Figure 7(c) and
Table 2). From Table 2, on the basis of mass fractions, it is
possible to calculate an overall puriﬁcation factor of ∼55 and
122-fold for NaBu-treated and untreated CHO cells, respec-
tively. The ∼2-fold increase in hPRL production obtained
in the presence of 1mM NaBu was also conﬁrmed after
puriﬁcation. Also remarkable are the perfectly coincident tR
values of the two CHO-derived hPRL preparations and of
theInternalReferenceofE.coli-derivedhPRL(19.58minutes
<t R < 19.72 minutes), conﬁrming their identical hydro-
dynamic properties in this long (60cm) HPSEC column
(Figure 7(c)). It has been reported that these properties can
be altered even by subtle modiﬁcations in the secondary and
tertiary structure of the molecule [32, 33].
3.3. Biological Assays. Finally, the two puriﬁed products
were tested for their biological activity against the Reference
Reagent for recombinant hPRL (WHO 97/714) in two
diﬀe r e n ti nv i t r ob i o a s s a y sb a s e do nN b 2a n dB a / F 3 - L L P
cells. The data illustrated in Figure 8 and reported in Table 3
show that apparently there were no diﬀerences between the
potencies of the puriﬁed products and that of the WHO
Reference Reagent.
4. Discussion
Previous studies have examined the production of recombi-
nant proteins by NaBu-treated CHO cells. Several of these
have discussed the beneﬁts or warned against the problems
caused by the presence of NaBu [14–16]. NaBu has, in fact,
been used for increasing the expression of foreign proteins
in animal cell cultures. It is recognized that NaBu alters
primarily chromatin structure through inhibition of histone
deacetylases, resulting in hyperacetylation of histones and,
consequently, alterations in DNA transcription. Therefore,
these alterations might be correlated with the modulation of
gene expression [11]. On the other hand, hyperacetylation
of histones in NaBu-treated mammalian cancer cell lines has
been shown to induce apoptosis mediated by activation of
caspase-3 activity, leading to the translation of putative cell
death proteins [34] and resulting in an increased possibility
of DNA cleavage [35].
In this study, we examined the expression level and
quality of hPRL directly in CHO cell-conditioned medium,
after adding diﬀerent amounts of NaBu. The diﬀerent NaBu
concentrations (0.25 to 2mM) remarkably increased hPRL
expression.
Addition of 1mM NaBu to the culture medium resulted
in a twofold increase in hPRL expression, with only a
relatively small decrease in cell growth compared with the
untreated control; this was conﬁrmed by RP-HPLC and
by Western blot and SDS-PAGE analysis. Although 2mM
and 4mM NaBu apparently induced a higher synthesis of
hPRL in the ﬁrst 24 hours of treatment, this synthesis
exhibited a decrease in the following days of culture. A
higher NaBu concentration (2 or 4mM) may be more
eﬀective in inhibiting the activity of histone deacetylases
and, consequently, increase the initial expression of proteins.
However, a greater modiﬁcation of the chromatin structure
could make the DNA more susceptible to apoptotic action
of endonucleases, leading to decreased productivity of
hPRL.
The addition of diﬀerent NaBu concentrations appar-
ently did not aﬀect the hydrophobicity or the hydrodynamic
proprieties of the hPRL molecule. This was inferred from
the fact that the tR values determined by RP-HPLC and
HPSEC were not signiﬁcantly altered by the NaBu treatment
relative to the untreated control or the internal reference
standard of periplasmic E. coli-derived hPRL. Our analytical
determinations, as a diﬀerence from other authors that
studied NaBu inﬂuence on heterologous protein production
with basis on immunological techniques [15–17], have been
mostly based on physicochemical methodologies.Journal of Biomedicine and Biotechnology 9
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Figure 8: Bioactivity of puriﬁed hPRL obtained from CHO cells treated or not with NaBu, determined via (a) Nb2 or (b) Ba/F3-LLP cell
assays against the International Standard of Recombinant hPRL (WHO 97/714). Values are the mean of two independent determinations.
The cell viability for diﬀerent concentrations of NaBu
was similar to that of the untreated control except in the
experiments with 4mM added NaBu. Therefore, the arrest
of cell growth after day 5 and similar decrease in cell viability
between 0–2mM NaBu was probably caused by removal of
dFBS from the culture medium and NaBu treatment during
the production process. This could make the CHO cell more
susceptible to apoptosis, leading to decreased cellular density
and viability.
Finally,twodiﬀerentinvitrobioassaysforpuriﬁedhPRL,
based on Nb2 and Ba/F3-LLP cells, were carried out. The
ﬁrst bioassay is the classical heterologous Nb2 rat lymphoma
cell proliferation assay [36], while the second is the recently
developed homologous Ba/F3-LLP assay [37], based on
murine pro-B lymphoma cells containing the sequence
encoding the human PRL receptor and previously utilized in
our laboratory [9, 27]. As described by Crowell et al. [38],
NaBu treatment can potentially modify the oligosaccharide
content of glycoproteins in various expression systems.
Although NaBu apparently has no eﬀect on the protein
structure of hPRL, there might be modiﬁcations of the
oligosaccharide structure of G-hPRL. In this regard, it is
known that the oligosaccharide nature and content can
inﬂuence the in vivo bioactivities of a glycoprotein [39–
42]. It is therefore important to note that the potency of
hPRL obtained in the presence of NaBu was comparable to
that of the Reference Reagent for recombinant hPRL (WHO
97/714). In conclusion, for the ﬁrst time recombinant hPRL
production from genetically modiﬁed CHO cells has been
signiﬁcant increased (∼2-fold) via NaBu addition, appar-
ently without compromising either its structure or function;
the quantitative and qualitative eﬀects of this addition have
been determined via accurate physicochemical techniques.
The same treatment can potentially be applied to other
hormones, for example, human thyrotropin (hTSH), which
is also produced in our laboratory [43]. The qualitative and
quantitative inﬂuence of this treatment on the carbohydrate
moieties of G-hPRL and possibly of other glycohormones
requires further investigation.
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